Ascendis Pharma (ASND) FDA Announcement summary

Introduction and purpose

• FDA approved Yorvipath (palopegteriparatide) as the first and only hormone replacement therapy for adult hypoparathyroidism in the U.S., addressing a significant unmet need for 70,000–90,000 adults.

• Yorvipath is a once-daily prodrug of parathyroid hormone designed for continuous 24-hour exposure.

• The approval reflects a commitment to addressing unmet medical needs in the hypoparathyroidism community, with company leadership and medical experts highlighting clinical value and launch plans.

Details of approval or decision

• Yorvipath is approved for adults with hypoparathyroidism, excluding acute post-surgical cases, with labeling reflecting broad eligibility.

• No REMS or black box warning is required; post-marketing studies will assess safety in lactation and pregnancy.

• FDA approval was based on global Phase 2 and Phase 3 clinical trials, with U.S. label allowing dosing up to 30 micrograms, though most patients require less.

• Titration was evaluated in adults with stable serum calcium on conventional therapy.

Impact on industry and stakeholders

• Yorvipath is expected to serve a U.S. patient population of 70,000–90,000, with 90% having insurance coverage.

• Launch leverages established rare disease commercial infrastructure, targeting ~6,000 healthcare providers covering 80% of the opportunity.

• The product is positioned as a multi-billion-dollar market opportunity and part of Ascendis' Vision 2030.

• Patient advocacy groups welcome the new treatment option beyond conventional therapy.